Page 2 - Classification Criteria News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The following is a summary of "Clinical Characteristics and Classification Criteria Performance in a Single-Center Cohort of 114 Patients With Immunoglobulin G4–Related Disease," published in the January 2023 issue of Rheumatology by Spandorfer, et al. IgG4-RD, also known as immunoglobulin G4-related disease, is a diverse fibroinflammatory disorder. The 2019 American College of Rheumatology (ACR)/European League

Bimekizumab treatment led to superior improvements in joint and skin efficacy outcomes at week 16 compared with placebo in patients with psoriatic arthritis and inadequate response or intolerance to TNFα inhibitors. The safety profile of bimekizumab was consistent with previous phase 3 studies in patients with plaque psoriasis, and studies of IL-17A inhibitors.

The dual interleukin-17 inhibitor was effective both in patients for whom TNF inhibitors failed and those who had never received a biologic disease-modifying antirheumatic drug in two trials.

The IL-23 inhibitor provides some relief for patients with active psoriatic arthritis whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase 3 trial.